To test this hypothesis, we compared the response of patient #1 pre- and post-doxorubicin cancer cells (days 305 and 732) to inhibitors of MEK and Akt (trametinib and MK220642), two important RTK effectors34. This evidence concerns the gene MAP2K7 and cancer.